Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

[1]  P. Gurbel,et al.  Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. , 2006, Journal of the American College of Cardiology.

[2]  B. Gersh,et al.  Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. , 2006, Journal of the American College of Cardiology.

[3]  P. Gurbel,et al.  What is the best measure of thrombotic risks—pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  P. Gurbel,et al.  Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. , 2005, Journal of the American College of Cardiology.

[5]  P. Gurbel,et al.  Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.

[6]  P. Gurbel,et al.  Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. , 2005, Journal of the American College of Cardiology.

[7]  Andrew J. Johnson,et al.  Adenine nucleotide metabolism in human blood – important roles for leukocytes and erythrocytes , 2005, Journal of thrombosis and haemostasis : JTH.

[8]  P. Gurbel,et al.  Resistance to antiplatelet drugs: current status and future research , 2005, Expert opinion on pharmacotherapy.

[9]  K. Mann,et al.  Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography , 2005, Journal of thrombosis and haemostasis : JTH.

[10]  W. Herzog,et al.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.

[11]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[12]  P. Gurbel,et al.  Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study , 2005, Circulation.

[13]  G. Rivard,et al.  Evaluation of the Profile of Thrombin Generation during the Process of Whole Blood Clotting as Assessed by Thromboelastography. , 2004 .

[14]  Kenichi A. Tanaka,et al.  Electron Microscopic Evaluations of Clot Morphology During Thrombelastography® , 2004, Anesthesia and analgesia.

[15]  A. Kastrati,et al.  Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy , 2004, Circulation.

[16]  P. Gurbel,et al.  Platelet activation in myocardial ischemic syndromes , 2004, Expert review of cardiovascular therapy.

[17]  H. Hod,et al.  Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.

[18]  U. Walter,et al.  CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation , 2003 .

[19]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[20]  P. Gurbel,et al.  Durability of platelet inhibition by clopidogrel. , 2003, The American journal of cardiology.

[21]  W. Cantor,et al.  Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. , 2000, American heart journal.

[22]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[23]  A. Germing.  Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention , 2005 .